Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Stephanie O. Page"'
Autor:
Muna R. Mian, Stephanie O. Page, Doyle M. Cummings, Shivajirao P. Patil, Jarrod Uhrig, James R. Powell, Kerry Sewell, Basem M. Mishriky
Publikováno v:
The Journal of Clinical Pharmacology. 60:980-991
Our aim was to explore whether the baseline hemoglobin A1c or the dose of sodium glucose cotransporter-2 inhibitor (SGLT-2i) chosen better predicted the efficacy of SGLT-2i versus dipeptidyl peptidase-4 inhibitor (DPP-4i) in type 2 diabetes. We searc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f6b81df4d49dbd58de292dffc4e5534
https://doi.org/10.1002/jcph.1599
https://doi.org/10.1002/jcph.1599
Autor:
Jarrod L, Uhrig, Stephanie O, Page, Basem M, Mishriky, Shivajirao P, Patil, James R, Powell, Kerry, Sewell, Muna R, Mian, Doyle M, Cummings
Publikováno v:
Journal of clinical pharmacologyReferences. 60(8)
Our aim was to explore whether the baseline hemoglobin A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1bcd232a9f736abe56cef07b192df979
https://pubmed.ncbi.nlm.nih.gov/32396236
https://pubmed.ncbi.nlm.nih.gov/32396236
Autor:
Doyle M. Cummings, Jarrod Uhrig, Shivajirao P. Patil, Stephanie O. Page, Kerry Sewell, Basem M. Mishriky, James R. Powell
Publikováno v:
Diabetes. 68
All FDA-approved SGLT2 inhibitors (SGLT2i) are currently available in two doses. While most SGLT2i have demonstrated CV benefit, there may be a difference in hemoglobin A1c (A1c) reduction between both doses. We performed a meta-analysis to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5baee961c321d17920d90139e1094aee
https://doi.org/10.2337/db19-2363-pub
https://doi.org/10.2337/db19-2363-pub
Autor:
Kerry Sewell, James R. Powell, Jarrod Uhrig, Doyle M. Cummings, Stephanie O. Page, Basem M. Mishriky, Muna R. Mian
Publikováno v:
Diabetes. 68
Both sodium glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are effective drugs known to reduce hemoglobin A1c (A1c). While some guidelines favor SGLT2i over DPP-4i, there is no clear criteria in choosing be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59c2e950c5a295ec0da64b4611893d2b
https://doi.org/10.2337/db19-2365-pub
https://doi.org/10.2337/db19-2365-pub